Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is SBC Medical Group Holdings (SBC) Stock Down -3.24% Today?

Why Is SBC Medical Group Holdings (SBC) Stock Down -3.24% Today?

Key Takeaways

  • SBC shares fell 3.24%, or $0.20, to $5.98 in Tuesday's opening session, extending a two-day pullback from Friday's spike.
  • No fresh company-specific news drove the decline; the move reads as continued profit-taking after a 37.64% single-session surge on Nov. 13 and a 15.92% drop on Nov. 16.
  • The earlier rally followed a decisive third-quarter beat — revenue up 35% to $58.6 million and EPS of $0.15 versus $0.11 expected — plus a capital and business alliance with AI developer NeuroBrain Dynamics.
  • Secondary pressure comes from investors scrutinizing the quality of that beat, since service-fee revisions, the Waqoo consolidation and one-off items did much of the work, and management ruled out a buyback.
  • Turnover has cooled sharply from roughly 1.7 million shares Friday and 1.2 million Monday, well above a 10-day average near 437,000 shares.
  • News Significance Score: 13/100 — No new catalyst and a move almost exactly in line with the stock's typical daily swing.
  • Nimble traders may access Price Targets, Earnings and Forecast pages on Tickeron for deeper coverage of the name.
  • Readers can also review Trending AI Robots to see which automated strategies currently rank highest.

Opening Summary

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) is an Irvine, California-based medical services organization that supplies marketing, staffing, procurement, technology and back-office support to roughly 293 aesthetic, dermatology, dental, orthopedic, fertility and alopecia clinics, primarily in Japan with growing operations in the United States and Southeast Asia. The stock traded at $5.98 early Tuesday, down $0.20, or 3.24%, from Monday's close of $6.18. The direction is clearly negative, and it follows a violent two-session reversal that took shares as high as $7.39 on Friday before a double-digit retreat on Monday. No verified news or fundamental development explained Tuesday's decline; the price action is consistent with traders trimming positions after an earnings-driven spike.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found for Tuesday's decline. No new regulatory filing, analyst action, contract announcement or macro release landed in the window before the move. The most plausible assessment is a continuation of profit-taking and position-shedding after Friday's post-earnings melt-up, which had pushed shares to a 52-week high of $7.39 from $5.34 in a single session. That gap higher left the stock extended well above its 20-day moving average, and Monday's 15.92% slide showed the bid was already thinning. Tuesday's modest follow-through, on early volume far below the previous two sessions, is consistent with a normal post-spike cooldown in a thinly traded micro-cap rather than a fresh bearish thesis. The stock has averaged an absolute daily move of about 3.3% over the past 60 sessions, so a decline of this size is unremarkable by its own standards.

The Post-Earnings Reset

The fundamental backdrop still matters. On Nov. 13, SBC reported third-quarter revenue of $58.58 million, up 35% year over year and comfortably above the roughly $49 million consensus, with earnings per share of $0.15 against $0.11 expected. Operating income rose 66% to $26.4 million and the operating margin widened to 45% from 37%, while adjusted EBITDA margin reached 47%. Management credited roughly $15 million of annualized service-fee revisions, the consolidation of Waqoo, higher equipment rental revenue and 36 net new clinic locations.

The same release contained items that now invite scrutiny: nine-month revenue rose just 13% and nine-month EPS only 3%, net margin narrowed to 27%, foreign-exchange losses replaced prior-year gains, and management declined to authorize a buyback despite holding $198 million in cash and $154 million in net cash. No formal numeric guidance was issued, and related-party revenue still accounts for the bulk of the top line. Those caveats, combined with a shareholder base in which the CEO controls roughly 80% of shares, give sellers a rationale to take profits quickly off a spike.

Market Context and Trading Activity

Friday's session traded more than triple the recent norm, and Monday's turnover remained elevated; Tuesday's opening minutes were comparatively quiet, suggesting the forced buying and panic selling have both faded. The stock remains up more than 100% over twelve months and roughly 16% over the past five sessions, so the current pullback is a modest retracement of a very large move rather than a breakdown. The decline is company-specific in nature, diverging from a broadly steadier tape for small-cap healthcare and aesthetic-medicine peers. Technically, the shares are holding above the $5.20–$5.35 congestion zone that capped the stock for most of October, but they now sit below Friday's closing high.

News Significance Score

The scale runs from 0, meaning no meaningful news and a routine price move, to 100, meaning transformative news and an extreme, rare move. The score for this session is 13 out of 100. The news component is weak for the day itself: no verified company announcement, filing or analyst action preceded the decline, leaving only the afterglow of a Nov. 13 report that the market has already digested. The price component is equally subdued. Tuesday's 3.24% decline is roughly 0.97 times the stock's typical daily move of about 3.3%, and moves of equal or greater magnitude occurred 17 times in the last 60 sessions, largely because the shares routinely swing several percent a day. Together, muted news and ordinary volatility produce a low reading.

What Comes Next for SBC

The next scheduled checkpoint is the fourth-quarter and full-year report, expected in late March 2027, with no numeric outlook yet in place to anchor expectations. Investors will watch whether service-fee revisions keep lifting management services revenue, whether same-clinic growth above 7% holds, and whether SG&A stays near the current baseline. Actionable data points before then include the November launch of an in-house blood biomarker testing program, progress on the six AI tools being co-developed with NeuroBrain Dynamics, and OrangeTwist site openings in the U.S. alongside plans for SBC-branded American clinics within six to twelve months. Risks include yen exposure on a largely Japan-denominated business, intensifying competition in Japanese aesthetic medicine, heavy related-party revenue concentration, governance concerns tied to ownership structure, and the tendency of the shares to give back post-earnings gains quickly.

Trending AI Robots

Tickeron maintains hundreds of AI-driven trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup adapts as market conditions shift. Reviewing the page helps traders see which automated approaches are working now and how they might complement their own research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SBC

SBC's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for SBC turned positive on November 13, 2026. Looking at past instances where SBC's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on SBC as a result. In 55 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

Following a +40.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBC advanced for three days, in 119 of 157 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 99 of 149 cases where SBC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.

Bearish Trend Analysis

The 10-day RSI Indicator for SBC moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 19 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 23 of 38 cases where SBC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

SBC broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.965) is normal, around the industry mean (13.131). P/E Ratio (10.500) is within average values for comparable stocks, (49.500). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (2.814). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (2.624) is also within normal values, averaging (26.240).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Industry description

The industry involves capturing raw data from various sources, extracting meaningful information from it and presenting it in a more accessible digital format. Many people would agree that data is the new gold, which makes data processing services all the more relevant for businesses’ strategic decisions. PayPal Holdings Inc., Fidelity National Information Services, Inc. and Automatic Data Processing, Inc. some of the big players in his burgeoning industry.

Market Cap

The average market capitalization across the Data Processing Services Industry is 3.14B. The market cap for tickers in the group ranges from 12.21K to 30.34B. EXPGY holds the highest valuation in this group at 30.34B. The lowest valued company is MOMT at 12.21K.

High and low price notable news

The average weekly price growth across all stocks in the Data Processing Services Industry was -3%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -7%. EGG experienced the highest price growth at 26%, while VCIG experienced the biggest fall at -37%.

Volume

The average weekly volume growth across all stocks in the Data Processing Services Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -31% and the average quarterly volume growth was -85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 41
Price Growth Rating: 60
SMR Rating: 77
Profit Risk Rating: 91
Seasonality Score: 4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry DataProcessingServices

Industry
N/A
Address
200 Spectrum Center Drive
Phone
+1 949 593-0250
Employees
863
Web
https://sbc-holdings.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.